October 2023

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

AT A GLANCE DaVita Inc. issued a statement in response to Novo Nordisk in relation ‘…to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality.’ Retatrutide, an Eil Lilly drug yet to be approved by the FDA, boasting ‘…Phase 2 trial results […]

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials. Read More »

Compounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day.

Hello all, It continues to be a fascinating, rapid and intense period of development in obesity and metabolic medicine. We learn something new virtually every week; we are very much looking forward to Obesity Week in Dallas, TX and the latest developments in evidence-based obesity science and treatments. In this Weekly Roundup, we have interesting articles including Novo

Compounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day. Read More »

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds.

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds.

Hello all, I hope everyone is having a wonderful weekend. I am back home after an intense week on the road, capped by a terrific two days at the ASMBS Weekend conference in New Orleans (where twenty30 health is a Bronze-level Corporate Council Member). It was an outstanding opportunity to connect with old friends and

Novo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending; GI side effects of GLP-1 meds. Read More »

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition

Hello Friends, Welcome to October. It has been an extraordinarily busy period here at twenty30 health; amongst many other activities and initiatives, yours’ truly has been hitting the conference circuit of late, and have had the opportunity to attend excellent events at DHNY in New York and Health Evolution in Nashville. I also had the

Risks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities in US obesity prevalence; Biden administration announces $8B for hunger, nutrition Read More »

Scroll to Top
Skip to content